NCT07081607View on ClinicalTrials.gov

Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 15, 2025

Primary Completion Date

July 16, 2026

Study Completion Date

July 16, 2028

Conditions
Peripheral T-Cell Lymphoma, Not Classified
Interventions
DRUG

golidocitinib with azacytidine and chidamide

"In Phase I, a 3+3 dose-escalation design will be adopted to enroll 3 to 12 participants, exploring the recommended Phase II dose (RP2D) at two dose levels of golidocitinib: 150 mg every other day (QOD) and 150 mg once daily (QD).~In Phase II, we aim to evaluate the efficacy and safety of golidocitinib RP2D po in combination with chidamide 20mg biw po and azacytidine 100mg d1-7, SC in patients with peripheral T-cell lymphoma"

All Listed Sponsors
lead

Ruijin Hospital

OTHER